|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MS4A7 |
Gene summary for MS4A7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MS4A7 | Gene ID | 58475 |
| Gene name | membrane spanning 4-domains A7 | |
| Gene Alias | 4SPAN2 | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R556 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58475 | MS4A7 | GSM4909297 | Human | Breast | IDC | 2.09e-14 | 5.32e-01 | 0.1517 |
| 58475 | MS4A7 | GSM4909298 | Human | Breast | IDC | 5.92e-20 | 4.80e-01 | 0.1551 |
| 58475 | MS4A7 | GSM4909302 | Human | Breast | IDC | 4.99e-50 | 1.06e+00 | 0.1545 |
| 58475 | MS4A7 | GSM4909304 | Human | Breast | IDC | 2.21e-48 | 8.32e-01 | 0.1636 |
| 58475 | MS4A7 | GSM4909306 | Human | Breast | IDC | 8.01e-16 | 4.10e-01 | 0.1564 |
| 58475 | MS4A7 | M5 | Human | Breast | IDC | 3.93e-17 | 1.10e+00 | 0.1598 |
| 58475 | MS4A7 | NCCBC14 | Human | Breast | DCIS | 4.76e-03 | 3.24e-01 | 0.2021 |
| 58475 | MS4A7 | NCCBC3 | Human | Breast | DCIS | 2.31e-08 | 4.21e-01 | 0.1198 |
| 58475 | MS4A7 | cirrhotic2 | Human | Liver | Cirrhotic | 1.75e-03 | -2.80e-02 | 0.0201 |
| 58475 | MS4A7 | HCC2 | Human | Liver | HCC | 7.40e-07 | 8.43e-01 | 0.5341 |
| 58475 | MS4A7 | Pt13.a | Human | Liver | HCC | 5.26e-16 | 5.73e-01 | 0.021 |
| 58475 | MS4A7 | Pt13.c | Human | Liver | HCC | 2.52e-08 | 6.45e-01 | 0.0076 |
| 58475 | MS4A7 | Pt14.d | Human | Liver | HCC | 1.32e-24 | 7.67e-01 | 0.0143 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MS4A7 | SNV | Missense_Mutation | rs774654772 | c.485N>T | p.Ser162Leu | p.S162L | Q9GZW8 | protein_coding | tolerated(0.25) | benign(0.04) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MS4A7 | SNV | Missense_Mutation | c.641N>T | p.Asn214Ile | p.N214I | Q9GZW8 | protein_coding | tolerated(0.43) | possibly_damaging(0.823) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| MS4A7 | deletion | Frame_Shift_Del | novel | c.337delN | p.Phe113LeufsTer3 | p.F113Lfs*3 | Q9GZW8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MS4A7 | SNV | Missense_Mutation | c.623N>C | p.Lys208Thr | p.K208T | Q9GZW8 | protein_coding | deleterious(0.02) | possibly_damaging(0.796) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| MS4A7 | SNV | Missense_Mutation | novel | c.13N>C | p.Ser5Pro | p.S5P | Q9GZW8 | protein_coding | tolerated(0.33) | benign(0) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MS4A7 | SNV | Missense_Mutation | novel | c.713C>A | p.Ser238Tyr | p.S238Y | Q9GZW8 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.543) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MS4A7 | SNV | Missense_Mutation | rs774654772 | c.485N>T | p.Ser162Leu | p.S162L | Q9GZW8 | protein_coding | tolerated(0.25) | benign(0.04) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MS4A7 | SNV | Missense_Mutation | novel | c.239N>T | p.Ser80Phe | p.S80F | Q9GZW8 | protein_coding | tolerated(0.11) | benign(0.169) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MS4A7 | SNV | Missense_Mutation | novel | c.413N>T | p.Ser138Ile | p.S138I | Q9GZW8 | protein_coding | tolerated(0.06) | possibly_damaging(0.837) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MS4A7 | SNV | Missense_Mutation | novel | c.184N>A | p.Leu62Met | p.L62M | Q9GZW8 | protein_coding | tolerated(0.06) | benign(0.172) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |